User profiles for Wen Zhong

Wen Zhong

- Verified email at umanitoba.ca - Cited by 6146

Wen Zhong

- Verified email at scilifelab.se - Cited by 2760

A single–cell type transcriptomics map of human tissues

M Karlsson, C Zhang, L Méar, W Zhong, A Digre… - Science …, 2021 - science.org
Advances in molecular profiling have opened up the possibility to map the expression of
genes in cells, tissues, and organs in the human body. Here, we combined single-cell …

An atlas of the protein-coding genes in the human, pig, and mouse brain

E Sjöstedt, W Zhong, L Fagerberg, M Karlsson… - Science, 2020 - science.org
INTRODUCTION The brain is the most complex organ of the mammalian body, boasting a
diverse physiology combined with intricate cellular organization. In an effort to expand our …

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

ZY Dong, WZ Zhong, XC Zhang, J Su, Z Xie, SY Liu… - Clinical cancer …, 2017 - AACR
Purpose: Although clinical studies have shown promise for targeting programmed cell death
protein-1 (PD-1) and ligand (PD-L1) signaling in non–small cell lung cancer (NSCLC), the …

[HTML][HTML] 3D bioprinting for biomedical devices and tissue engineering: A review of recent trends and advances

S Derakhshanfar, R Mbeleck, K Xu, X Zhang, W Zhong… - Bioactive materials, 2018 - Elsevier
3D printing, an additive manufacturing based technology for precise 3D construction, is currently
widely employed to enhance applicability and function of cell laden scaffolds. Research …

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label …

WZ Zhong, Q Wang, WM Mao, ST Xu, L Wu… - The Lancet …, 2018 - thelancet.com
Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …

[HTML][HTML] Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on …

YL Wu, WZ Zhong, LY Li, XT Zhang, L Zhang… - Journal of Thoracic …, 2007 - Elsevier
Background Convincing data on epidermal growth factor receptor (EGFR) mutations in
Chinese patients with non-small-cell lung cancer (NSCLC) remain limited. We investigated the …

Nitric oxide donors: chemical activities and biological applications

PG Wang, M Xian, X Tang, X Wu, Z Wen, T Cai… - Chemical …, 2002 - ACS Publications
Although the use of glyceryl trinitrate (GTN) for medicinal purposes dates back to more than
150 years, little had been revealed about its physiological mechanism of action before the …

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A …

WZ Zhong, KN Chen, C Chen, CD Gu… - Journal of clinical …, 2019 - ascopubs.org
PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation-positive …

[HTML][HTML] Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 …

WZ Zhong, Q Wang, WM Mao, ST Xu, L Wu… - Journal of clinical …, 2021 - ncbi.nlm.nih.gov
METHODS From September 2011 to April 2014, 222 patients from 27 sites were randomly
assigned 1: 1 to adjuvant gefitinib (n= 111) or VP (n= 111). Patients with resected stage II-IIIA (…

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a …

…, F Rivera, E Elez, DT Le, T Yoshino, WY Zhong… - The Lancet …, 2022 - thelancet.com
Background Pembrolizumab has shown improved progression-free survival versus
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch repair-…